Polycystic liver disease often occurs in association with autosomal dominant polycystic kidney disease (ADPKD; OMIM 173900 and OMIM 173910), but it also exists as isolated autosomal dominant polycystic liver disease (ADPLD; OMIM 174050). Mutations in PRKCSH 1,2 cause ADPLD and there is evidence of genetic heterogeneity 3 . Of 66 unrelated individuals affected with ADPLD 4, 5 , mutations in PRKCSH were excluded in 57 probands by direct sequencing. Of these, 10 individuals belonged to families with multiple affected individuals. Four of the five largest kindreds ( Supplementary Fig. 1 online) were previously reported: families A-6 (ref. 6 ), B-7 (ref. 7) , F-1 and F-4 (ref. 3) . We carried out a genome-wide analysis for linkage at ∼10-cM resolution in all ten families (comprising 43 affected individuals, 18 unaffected individuals and 2 spouses) by genotyping 394 microsatellite markers.
We set the allele frequency for the gene underlying ADPLD to 0.0002, the phenocopy rate to 0.01 and the heterozygous disease penetrance to 95% (ref. 4) . We assigned all phenotypic data before genotyping. We calculated lod scores for the entire marker set using MLINK and LOD-SCORE for two-point analysis and GENEHUNTER (version 2.1) for multipoint analysis (Fig. 1a and Supplementary Table 1 online). We used the suggested genome-wide significance threshold for parametric analyses with many independent families, lod >3.3, to establish linkage.
Only one region of the genome, on chromosome 6q, met this criterion, yielding a maximum multipoint lod score, Ζ max , of 6.0 (Fig. 1a) . The 1-lod support interval among the ten families was ∼7 cM, corresponding to ∼8 Mb on the physical map between D6S1021 and D6S474 (Fig. 1a) . Under models of heterogeneity, we obtained a maximum multipoint lod score of 6.4 at α = 0.81 with the same 1-lod support interval (data not shown). The genetic interval between D6S1021 and D6S474 was also supported by haplotype analysis in the three families with the highest individual multipoint lod scores (Fig. 1b) .
Examination of the annotated sequence in the human MapViewer identified ∼39 genes and a number of putative open reading frames or hypothetical genes ( Fig. 1c-f ). We initially focused on genes that are expressed in liver tissue (as shown by RT-PCR) and that may be functionally linked to PRKCSH through a role in protein maturation in the ER. SEC63 met these criteria. We screened the 21-exon coding sequence and flanking splice sequences of SEC63 by direct sequencing of amplified genomic PCR products (primer sequences on request). We detected seven heterozygous sequence variants in 8 of 57 probands, including the five families in whom we found the highest lod scores with chromosome 6 markers ( Table 1 and Supplementary Fig. 2 online). Mutations were located throughout the gene from exon 2 to exon 19 ( Fig. 1 c-f) . We found two insertion-deletion mutations resulting in frameshifts with premature chain termination, two nonsense codon mutations and two mutations predicted to disrupt splice donor-acceptor sites. These variants were not found in 192 normal chromosomes. The final variant, 1702delGAA, resulted in the inframe deletion of one of three successive glutamic acid residues (amino acids 566-568). This variant was not found in 360 normal chromosomes and is probably pathogenic.
Mutation 173G→A, resulting in a nonsense codon W58X, occurred in two probands from the central US who were not known to be related. Three probands from Finland (in families F-1, F-4 and F-226) had different mutations. The unique nature of most mutations is consistent with the idea that mutations in SEC63 that cause ADPLD, like those in PRKCSH 1,2 and in the genes associated with polycystic kidney disease [8] [9] [10] , probably arose independently. We found an additional 11 sequence variants, 7 of which result in amino acid substitutions, in samples from both affected individuals and controls (Supplementary Table 2 online). Although cysts occur only in the liver, Sec63 was expressed in all tissues tested ( Supplementary Fig. 3 online) . Expression in the liver was roughly two times higher than in kidney and testis when densitometrically normalized to β-actin loading ( Supplementary Fig. 3 online) .
In summary, we identified a second gene associated with ADPLD. We found mutations in SEC63 in 8 of 66 probands (∼12%) in our sample that included both familial cases and individual probands not known to have a family history of ADPLD. Mutations in PRKCSH and SEC63 together account for less than one-third of ADPLD cases in this cohort, indicating that there is at least one more locus associated with this disease.
SEC63 encodes an integral membrane protein of the ER that is highly conserved from yeast to man. It is part of the multicomponent translocon that comprises the protein translocation machinery for integral membrane and secreted proteins. There are two targeting pathways to the Sec translocons: the cotranslational or signal recognition particle (SRP)-dependent pathway and the post-translational or SRP-independent pathway (reviewed in ref. 11). SEC63 is required in both post-translational and cotranslational pathways 12 . The cotranslational pathway, in which the ribosome is directly complexed with the Sec translocon and extrudes the nascent peptide through it, is the main pathway in mammalian cells, including lumen-forming epithelia such as the bile duct. Cotranslational maturation events include signal peptide cleavage, transfer and trimming of N-linked glycans, disulfide bond formation, transmembrane domain integration, chaperone binding and protein folding 11, 13 . The transfer and trimming of N-glycans notably involves the activity of glucosidase II (GII), the β subunit of which, PRKCSH, was the first gene found to be associated with ADPLD. PRKCSH-dependent GII activity promotes proper folding and maturation of glycoproteins in the calnexin-calreticulin cycle 14 , a process that occurs immediately downstream of the translocon. This is the functional link between the two genes known to be associated with ADPLD 11 . Other genes involved in these processes are functional candidates for ADPLD.
If ADPLD, like ADPKD, occurs by a cellular recessive, two-hit mechanism, then mutations in either SEC63 or PRKCSH will result in loss of proper folding of integral membrane or secreted glycoproteins in bile duct cells that have undergone somatic second hits. Proteins that do not fold properly are targeted for degradation 14 . One possible molecu- protein and the location of mutations detected in individuals with ADPLD. SEC63 is an integral protein of the ER membrane with three transmembrane spans (TM1-TM3), a luminal N terminus, a cytoplasmic C terminus containing a SEC63 domain (yellow) with a coiled-coil region (CC, green) and a DnaJ domain (red) between TM2 and TM3 facing the ER luminal aspect. Within the cotranslational pathway, the DnaJ domain of SEC63 acts as a docking site localizing BiP to the luminal exit site of the Sec translocon 11, 12 . The C terminus is thought to physically interact with other Sec translocon components.
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VOLUME 36 | NUMBER 6 | JUNE 2004 NATURE GENETICS Using microarray gene expression data from several Drosophila species and strains, we show that duplicated genes, compared with single-copy genes, significantly increase gene expression diversity during development. We show further that duplicate genes tend to cause expression divergences between Drosophila species (or strains) to evolve faster than do single-copy genes. This conclusion is also supported by data from different yeast strains.
Different copies of duplicate genes can become specialized at different developmental stages (e.g., different copies of Hox genes 1,2 ). Therefore, duplicate genes should have more diversified expression profiles than single-copy genes during the development of an individual. Moreover, the redundancy conferred by duplicate genes for the regulation of a function may facilitate organismal adaptation to environmental changes, so that the expression patterns of duplicate genes are, in general, expected to diverge between species faster than those of singlecopy genes. The latter hypothesis is particularly interesting because changes in gene expression may lead to important phenotypic evolution 3, 4 . A direct examination of these two hypotheses at the genomic level, however, was not possible until high-throughput gene expression data became available. In this study, we tested the two predictions using microarray data from fruit flies and yeast. We first used the data on gene expression during the start of metamorphosis (between the late third-instar larval and white prepupal stages) in three species of the D. melanogaster subgroup. This data set included 11,723 genes from a study investigating the evolution of gene expression in four inbred strains of D. melanogaster (Canton S, Oregon R, Samarkand and Netherlands2), one inbred strain of D. simulans and one Percent with changes in expression 60.5 87.8 *A gene family was considered to have changes in expression during the start of metamorphosis if one or more of its members had a significant change in expression across the start of metamorphosis in at least one of the six strains studied. For the comparison between single-copy genes and gene families, χ 2 = 242.1, degrees of freedom (d.f.) = 1, P ≈ 0. The results were essentially the same if the numbers of duplicate genes were used in the comparison, that is, a significantly higher proportion of duplicate genes than of single-copy genes had changes in gene expression during the start of metamorphosis (χ 2 = 93.
between at least two of the six strains during the start of metamorphosis. This proportion is much higher than that of single-copy genes (1,202 of 3,356; 36%; Table 2 ). Individual pair-wise comparisons between strains also supported this conclusion (data not shown).
We also examined differences in expression of duplicated genes between two yeast strains and observed a similar pattern. A study dissecting transcriptional regulation in the budding yeast 8 compared gene expression profiles between a laboratory strain (BY) and a wild strain (RM) of Saccharomyces cerevisiae. Differential expression between strains was detected for more than 1,500 genes (of 6,215 genes; Supplementary Methods online). Using these data, we found that a significantly higher proportion of duplicate genes than of single-copy genes had expression patterns that differed between the two strains of yeast ( Table 2) . Therefore, the results from both fruit flies and yeast indicate that duplicate genes cause expression divergences to evolve between species (or strains) faster than single-copy genes. This conclusion also holds true for very old duplicate genes (Supplementary Table 3 online).
In both within-genome and between-genome comparisons, we found that duplicate genes were more likely than single-copy genes to show changes in expression profiles. These conclusions did not change when we used different criteria to define duplicate genes and single-copy genes (Supplementary Table 4 online). Furthermore, we found that protein function, codon usage bias or gene evolutionary rate could not explain the observed patterns (data not shown). The observed association between gene duplication and increased gene expression diversity within and between species is important for two reasons. First, divergence in expression between duplicate genes may lead to functional specialization, which is a means of retaining both copies of duplicate genes in a genome 9, 10 . Second, we found that relatively old duplicate gene pairs still contributed to expression diversity between strains, and earlier studies showed that functional redundancy may exist between distantly related duplicate genes 11, 12 . Thus, during speciation or adaptation, these functionally redundant copies could have more chances (less constraint) to adapt to new environmental and physiological conditions than single-copy genes. The results of this study are particularly interesting in light of the proposal that changes in gene expression can lead to important phenotypic changes in evolution [13] [14] [15] , which might lead to species differentiation. As more intra-and inter-species gene expression data become available at the genome level, the relationships among gene duplication, gene expression evolution and phenotypic change will be better understood. inbred strain of D. yakuba 5 ; we compared larvae and prepupae eight times for each lineage to obtain more accurate estimates of gene expression (Supplementary Methods online). We estimated developmental changes in expression of each gene in each lineage separately using an ANOVA model 5 . We used the 95% confidence intervals to determine first whether a gene was differentially expressed across the start of metamorphosis in a particular lineage, and second, whether the developmental change differed between lineages (that is, whether it had evolved; see ref. 5 for methodology). These lists of genes whose expression changed during development or differed between lineages were the starting point of this study.
We conducted two analyses. First, we examined whether expression levels of duplicate genes changed significantly across the start of metamorphosis more often than those of single-copy genes (a withingenome comparison). We used strict criteria to define duplicate and single-copy genes (Supplementary Methods online; relaxation of the criteria led to the same conclusions). Furthermore, to avoid crosshybridization, we included in the analysis only those duplicate genes that had K S values (number of substitutions per synonymous site) to their closest paralogs of >0.5 (Supplementary Methods online; all the following results were the same without this restriction). Because each gene family originated from one common ancestor, we regarded each gene family as a uniquely represented entry in our first analysis 6 . For this purpose, we grouped duplicate genes into families (see Supplementary  Fig. 1 online for the family size distribution). We identified 3,332 duplicate genes belonging to 932 gene families in the data set. In 818 gene families, one or more family members had significant changes in expression across the start of metamorphosis in at least one strain ( Table 1) . The proportion of gene families that showed changes in gene expression was significantly higher (818 of 932; 88%) than that for single-copy genes (2,030 of 3,356; 60%). We obtained similar results in individual strains (Supplementary Table 1 online). Considering each duplicate gene individually, the proportion of duplicate genes (72%, 2,389 genes) that showed changes in expression across the start of metamorphosis was still much higher than that of single-copy genes (60% ; Table 1 and  Supplementary Table 2 online).
These observations suggest that duplication of a developmentally regulated gene is more likely to be advantageous than duplication of a gene that is not involved in development. One possible reason for this is that gene duplication can provide regulatory diversity to an organism during development 7 . To determine whether this is the case, we investigated differences in gene expression patterns in each gene family. Of the 818 gene families that include genes with developmental changes in expression, we found that about 70% (545) had different expression profiles (increase, no expression change or decrease) between individual genes in each family. The actual proportion might be higher, because we excluded some members of certain gene families from the expression data set. These results indicate that duplicate genes significantly increase the gene expression diversity of an organism. This conclusion is strengthened by the fact that probable differences in spatial expression patterns between different tissues were not taken into account in the above analysis.
Second, we made a between-genome comparison by examining differences in gene expression between species and between different strains within species. Of the 3,332 duplicate genes in the data set, 1,593 of them (∼50%) had significantly different expression patterns
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VOLUME 36 | NUMBER 6 | JUNE 2004 NATURE GENETICS We assessed 12 individuals with FTC from two large kindreds of Druze and African-American origin (Fig. 1a ) that have been extensively described 1,2 . All affected individuals reported recurrent painful, calcified subcutaneous masses of up to 1 kg (Fig. 1b) , often resulting in secondary infection and incapacitating mutilation. Three individuals developed deep periarticular tumors (Fig. 1b) , and one succumbed to the disease. All affected individuals had hyperphosphatemia (family 1, 6.2-8.5 mg dl -1 ; family 2, 5.2-6.6 mg dl -1 ) but normal levels of calcium, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3.
With informed consent of all participants, we obtained DNA samples and carried out a genome-wide scan using 362 microsatellite markers (Research Genetics) in family 1. Consanguinity in this kindred allowed us to apply homozygosity mapping to identify in all affected individuals a 15-Mb segment identical by descent, flanked by D2S142 and D2S2284/D2S2177 on 2q24-q31 (Fig. 1) . We obtained a maximum multipoint lod score of 6.7 (HOMOZ 3 ). Multipoint linkage analysis in family 2 using seven markers in this critical region further reduced the interval to 3 Mb flanked by D2S111 and D2S1776 (Fig. 1) and yielded a maximum multipoint lod score of 3.4 (GeneHunter 4 ).
Using Mapviewer, we identified 11 genes in the 3-Mb region associated with FTC. Of these, B3GALT1, SCN7A, SCN9A, SCN1A and STK39 have roles in neural or neuroendocrine tissues; the functions of TAIP-2, CMYA3, FLJ11457, LOC90643 and LASS6 are mostly unknown. The last positional candidate gene, GALNT3, encodes the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (ppGaNTase-T3; ref. 5). ppGaNTase-T3 belongs to a large family of Golgi-associated biosynthetic enzymes that transfer GalNac from the sugar donor UDP-GalNac to serine and threonine residues and are thereby responsible for initiating O-glycan synthesis, a prevalent form of post-translational modification 6 . RT-PCR analysis showed strong expression of GALNT3 in the skin and kidneys, two tissues of functional relevance to the pathogenesis of FTC 1,2 (Fig. 2a) . Using balanced primer pairs, we screened PCR amplicons of all ten coding exons and conserved splice sites of GALNT3 for pathogenic mutations in the genomic DNA of affected individuals (primer pairs and PCR conditions are available on request). Members of the Druze family carried a homozygous G→A transition at position 1524+1 (from the ATG translation start site), resulting in disruption of the intron 7 donor splice site consensus sequence (Fig. 2b) . Affected individuals of family 2 were compound heterozygous with respect to a nonsense mutation 484C→T (starting from the ATG; resulting in the amino acid substitution R162X) in exon 1 and a splice site mutation (1524+5G→A) in intron 7 (Fig. 2b) . PCR-RFLP analysis confirmed complete cosegregation of the mutations with the disease phenotype (Fig. 2c) . All three mutations were not present in a panel of at least 290 chromosomes derived from healthy unrelated individuals.
Nonsense mutation 484C→T is expected to result in a nonfunctional null allele causing premature termination of protein translation. Mutations 1524+1G→A and 1524+5G→A alter the same splice donor site in intron 7. In contrast to the normal splicing score of 0.93 obtained for the intron 7 splice donor site predicted by the Splice Site Prediction by Neural Network software, the calculated score of this sequence carrying a G→A mutation at position 1524+1 or 1524+5 was 0.00. To further
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assess the consequences of the 1524+1G→A splice site mutation, we analyzed GALNT3 gene transcription by RT-PCR, using RNA extracted from skin biopsy and blood samples from affected individuals in family 1. We detected no wild-type transcript and small amounts of an aberrant splice variant lacking the exon 7 nucleotide sequence (Fig. 2d) . Exon 7 skipping leads to an in-frame deletion of 44 amino acid residues, destroying most of the linker region located between the catalytic domain and the ricin-like domain of the glycosyltransferase.
Since the original description of FTC more than a century ago by Giard, the pathogenesis of this disease has been the subject of many investigations but has remained mostly elusive. Hyperphosphatemia, secondary to increased renal phosphate retention, is the major metabolic abnormality associated with FTC and is accompanied by inappropriately normal or elevated levels of PTH and 1,25-dihydroxyvitamin D3, two essential regulators of phosphate metabolism 7 . Additional molecules, such as fibroblast growth factor 23 (FGF23), secreted frizzledrelated protein 4 (SFRP4) and matrix extracellular phosphoglycoprotein (MEPE), may also have roles in controlling circulating phosphate levels 7, 8 . Those proteins have characteristics predicted for a new class of phosphate-regulating proteins collectively called phosphatonins 8 because they modulate circulating phosphate levels [9] [10] [11] [12] . FTC seems to represent the metabolic mirror image of hypophosphatemic rickets caused by mutations in PHEX (OMIM 307800) and in FGF23 (OMIM 193100) 7, 8 , which is characterized by decreased phosphate levels, decreased renal tubular phosphate reabsorption and inappropriately normal or decreased levels of 1,25-dihydroxyvitamin D3 (ref. 13) . Hence, FGF23 and other phosphatonin genes have been considered prime candidates for underlying FTC 13 .
Our results suggest a role for ppGaNTase-T3-mediated glycosylation in controlling phosphatonin activity. Although the NetOGlyc 3.0 software identified potential O-glycosylation sites in FGF23 (setting O-glycosylation score significance at >0.5), this molecule probably does not mediate the deleterious effects of GALNT3 mutations in FTC. Impaired FGF23 activity in a mouse model led to prominent bone tissue abnormalities 14 , which were absent in the individuals with FTC whom we studied. FGF23 circulating levels measured by ELISA (Immutopics) were significantly elevated in six individuals with FTC (1710 ± 864 RU ml -1 ) as compared with six unaffected controls (56 ± 38 RU ml -1 ), possibly reflecting a compensatory response to hyperphosphatemia. Thus, ppGaNTase-T3 may affect phosphate homeostasis by modulating the activity of another phosphatonin or PHEX 13 . Alternatively, it may directly regulate noncirculating elements in tissues where GALNT3 is expressed (Fig. 2a  and ref. 5) , such as the skin (where calcium deposition occurs 1,2 ), bone (where candidate phosphatonins are expressed 7, 8 ), kidneys and gastrointestinal tract (where phosphate transport occurs 13 ). Given the existence of more than 20 ppGaNTase isoforms 6 , substrate specificity or functional redundancy may account for the restricted nature of the FTC phenotype despite widespread GALNT3 expression in tissues.
ppGaNTase-T3 may not be the sole regulator of phosphate homeostasis in peripheral tissues, as FTC can also present with normal blood phosphate levels 15 . Using haplotype analysis in four families with normophosphatemic FTC, we excluded linkage of this FTC variant to 2q24-q31 (data not shown), suggesting that normophosphatemic and hyperphosphatemic FTC are nonallelic disorders. .1 cM showed a maximum multipoint lod score of 6.7 at D2S111 (using HOMOZ). The multipoint linkage map in the nonconsanguineous family 2 (right panel) using seven microsatellite markers shows a peak lod score of 3.4 for markers D2S2363 and D2S1379 (using GeneHunter).
In summary, our results establish autosomal recessive mutations in GALNT3 as the molecular cause of hyperphosphatemic FTC and demonstrate the pathological consequences of a genetic defect in a mucin-type O-glycosylation pathway. The identification of the gene underlying FTC should not only benefit the affected families, to whom molecular testing can now be offered, but may also shed new light on the mechanisms regulating phosphate metabolism in health and disease, with obvious implications for the treatment of acquired disorders manifesting with hyperphosphatemic calcinosis, such as chronic renal failure.
URLs.
Mapviewer is available at http://www.ncbi.nlm.nih.gov/mapview/. Splice Site Prediction by Neural Network is available at http://www.fruitfly. org/seq_tools/splice.html. NetOGlyc 3.0 is available at http://www.cbs.dtu.dk/ services/NetOGlyc. The role of the primary mammalian DNA methyltransferase, DNMT1, in maintaining CpG island methylation in human colon cancer cells has recently been questioned. This controversy has arisen from discrepancies between genetic knockout and RNA interference-mediated knockdown studies. Here, we re-examined the RNA interference-based approach and found that hypermethylation of single-copy genes is maintained in cells transiently and stably depleted of DNMT1.
The accumulation of 5-methylcytosine in the promoters of tumorsuppressor genes correlates with their transcriptionally silent state and is a crucial pathway for gene inactivation in human neoplasia 1 . The role of DNMT1 in maintaining CpG methylation in human cancer cells, extrapolated from studies done during early mouse development 2 , was re-evaluated when it was determined that CpG island hypermethylation could be maintained after genetic deletion of the DNMT1 locus in the human colorectal carcinoma cell line HCT116 (ref. 3) . Later experiments showed a cooperative role for the enzymes DNMT1 and DNMT3b in maintaining nearly all genomic CpG methylation 4 . HCT116 cells depleted of DNMT1 by treatment with antisense or small interfering RNA (siRNA) showed complete loss of CpG methylation in the promoter of the tumor-suppressor gene CDKN2A, leading to the conclusion that DNMT1 is essential in maintaining CpG methylation in these cells 5 .
To address this controversy, we depleted HCT116 cells of DNMT1 using the same double-stranded RNA oligonucleotides (siDNMT1) used previously 5 (Fig. 1a) and included mismatched siRNA oligonucleotides (siMM) and reagent-only treatments as controls. homologous recombination and are proficient in mismatch repair but retain high transfection efficiency. Like HCT116 cells, SW480 cells depleted of DNMT1 protein and enzyme activity retained methylation and gene silencing at all of the loci that we analyzed ( Supplementary  Fig. 3 online) . One criticism of the genetic knockout strategy is that only the rare clones that could tolerate loss of the enzyme survived the homologous recombination and selection that was required to delete the DNMT1 locus 5 . To address this issue, we generated vectors expressing short hairpin RNA (shRNA) species encoding the same oligonucleotide sequences as siMM (pshMM) and siDNMT1 (pshDNMT1) 11 . After transfection and drug selection, we found no statistically significant differences in colony formation between the groups treated with pshMM (108 ± 8) and pshDNMT1 (101 ± 5; Fig.  2a) . We randomly isolated and expanded two pshMM and ten pshDNMT1 clones for analysis. As expected, DNMT1 protein levels and enzyme activity in pshMM clones were similar to those in parental wild-type HCT116 cells (Fig. 2b,c) . The pshDNMT1 clones had one of three distinct knockdown phenotypes. The first group (20%) showed no detectable changes in protein levels or methyltransferase activity. Most clones had a 60-90% reduction in enzyme amount and activity, equivalent to the reductions observed in the transiently depleted cultures. Thirty percent of clones showed a 95% reduction in methyltransferase activity and an absence of protein, identical to the DNMT1-knockout cells 3 .
MSP analysis of cell lines with different levels of DNMT1 indicated that CpG methylation was maintained in the CDKN2A, SFRP1, GATA4 and GATA5 promoters (Fig. 2d) . We further analyzed the We collected cells every 48 h to monitor protein amount, enzyme activity and growth ( Supplementary Fig. 1 online) . Quantitative western-blot analysis showed an average reduction of 92% ± 3% in DNMT1 protein levels (Fig. 1b) , and enzyme activity was reduced by 59% ± 5% throughout the 30-d period (Fig. 1c) . These results are comparable to those obtained previously 5 .
We analyzed CpG methylation at the CDKN2A locus by methylation-specific PCR (MSP) 6 . This classical tumor-suppressor gene is completely inactivated in HCT116 cells by a frameshift mutation of one unmethylated allele and hypermethylation of the other allele 7 . We detected both methylated and unmethylated alleles in the CDKN2A promoter during the entire transfection period (Fig. 1d) . We observed similar preservation of CpG methylation for SFRP1, GATA4 and GATA5 promoters, which are fully hypermethylated in wild-type HCT116 cells (Fig. 1d) 8, 9 . Corresponding retention of gene silencing for SFRP1, GATA4 and GATA5 was confirmed by RT-PCR (Fig. 1e) .
We next assessed the methylation status of 35 CpG dinucleotides in the CDKN2A promoter using the bisulfite sequencing technique 10 . By using primers that amplify the region spanning the frameshift mutation, we could distinguish between wild-type (methylated) and mutated (unmethylated) alleles ( Supplementary Fig. 2 online) . We found that CpG residues on the wild-type alleles were methylated at 92% of sites in cells treated with siMM and 95% of sites (on d 6) and 97% of sites (on d 14) in cells treated with siDNMT1 (Fig. 1f) .
To address whether the phenotype of DNMT1 depletion in HCT116 cells is representative of colorectal cancer cell lines, we transiently knocked down expression of DNMT1 in SW480 cells ( Supplementary  Fig. 3 online) . These cells, unlike HCT116 cells, have almost no methylation status of the CDKN2A promoter using bisulfite sequencing (Fig. 2e) . The clone expressing shMM showed methylation at >99% of the CpGs on the wild-type alleles. Clone 29 (intermediate DNMT1 knockdown) retained 98% methylation. The clones that were severely depleted of DNMT1 showed 98% (clone 30) and 94% (clone 27) retention of methylation.
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Our results suggest that the low frequency of DNMT1 genetic disruption does not reflect selection of rare clones but may result from well-documented differences in targeting frequencies between loci 12 . Stable knockdown of DNMT1 by shRNA was 30 times more efficient than genetic targeting. The difference may be due to the molecular mechanism (homologous recombination versus translation interference) underlying each strategy 13 .
Using both siRNA and shRNA approaches, we found that human colorectal cancer cells can maintain CpG methylation of tumorsuppressor genes in the absence of DNMT1. These findings, consistent with the phenotype of DNMT1-knockout HCT116 cells, may have important implications for the design of pharmacological interventions targeting DNA methyltransferases. Our studies suggest that inactivating DNMT1 enzyme alone may be insufficient to re-express epigenetically silenced tumor-suppressor genes and restore normal cellular growth in colorectal cancer cells. Given the compensatory functions of other DNA methyltransferases 4 and the emerging importance of chromatin modifying enzymes 14, 15 in establishing and maintaining epigenetic gene silencing, development of combinatorial therapeutic strategies should be considered.
Note: Supplementary information is available on the Nature Genetics website.
